“Is sotagliflozin a ‘wonder drug’? A review of its impact on cardiovascular, diabetic, renal, neuroprotective, and hepatic outcomes”
Eeshal Fatima(Services Institute of Medical Sciences), Aymar Akilimali(Roslin Institute), Hamza Irfan(Shaikh Zayed Postgraduate Medical Institute), Jyoti Jain, Faiza Fatima(Services Institute of Medical Sciences), Ayesha Sehar(King Edward Medical University)
Cited by 4
Related Papers
Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
|Annals of Medicine and Surgery|2024|87
Impacts of the advancement in artificial intelligence on laboratory medicine in low‐ and middle‐income countries: Challenges and recommendations—A literature review
|Health Science Reports|2024|62
Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
|Annals of Medicine and Surgery|2023|30
Self-medication and Anti-malarial Drug Resistance in the Democratic Republic of the Congo (DRC): A silent threat
|Tropical Medicine and Health|2022|29